Transurethral microwave thermotherapy for the treatment of BPH: still a challenger?
Minimally invasive therapies for treatment of benign prostatic hyperplasia (BPH) compete with the gold standard transurethral resection of the prostate (TURP). Comparisons of efficacy and safety have broadened the knowledge of different treatment modalities. Concerns of quality of life such as unaltered sexual function as well as cost considerations drive the market to develop techniques of lower level invasiveness. Among the competitors the office based transurethral microwave thermotherapy (TUMT) provides the broadest scale of scientific data. Numerous manufacturers sell various modifications of this technology. According to different clinical studies TUMT proved to be an effective, safe, and durable therapy for the treatment of lower urinary tract symptoms (LUTS) secondary to BPH. However, TURP still holds the steadier long-term results and is more effective to reduce obstruction as well as other LUTS.
Herrmann
T R W
TR
Department of Urology and Pediatric Urology, Medical School of Hannover (MHH), Carl Neuberg Street 1, 30625, Hannover, Germany. herrmann.thomas@trwh.de
Gross
A J
AJ
Schultheiss
D
D
Kaufmann
P M
PM
Jonas
U
U
Burchardt
M
M
D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000601:surgery*; D020728:Transurethral Resection of Prostate / Q000009:adverse effects; D016896:Treatment Outcome